ParkinsonCanadaV1, Main, Exploration, bibRecord, 001C77

The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates

Identifieur interne : 001C77 ( Main/Exploration ); précédent : 001C76; suivant : 001C78

The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates

Auteurs : Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0474325

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Dyskinésie, Pathologie du système nerveux, Récepteur α2-adrénergique, Fipamézole, Lévodopa, Primates.

English descriptors

KwdEn :
- Dyskinesia, Fipamezole, Levodopa, Nervous system diseases, Parkinson disease, Primates, α2-Adrenergic receptor.

Abstract

Reduction in the antiparkinsonian benefit of levodopa is a major complication of long-term levodopa treatment in advanced Parkinson's disease (PD). Such loss of benefit arises because of reduced duration of action and appearance of disabling dyskinesia. We assess the potential of the α₂ adrenergic antagonist fipamezole to reduce motor complications in parkinsonian macaques. MPTP-lesioned macaques were treated acutely with fipamezole (10 mg/kg) alone and in combination with two doses of levodopa. Fipamezole extended both duration and quality of antiparkinsonian action of levodopa. Duration of antiparkinsonian action, on time, was increased by up to 75% while "good-quality" on time, i.e., that not associated with disabling dyskinesia, was increased by up to 98%. Combination of fipamezole with the lower dose of levodopa provided antiparkinsonian benefit at least equivalent to that provided by the higher dose levodopa alone. However, with the combination, antiparkinsonian benefit was of much better quality. The proportion of on time without disabling dyskinesia (79%) was significantly greater than that with high dose levodopa alone (45%). Increased duration and quality of levodopa action may represent therapeutically valuable actions of α₂ adrenergic antagonists.

Affiliations:

Australie, Canada, Suisse

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000382
to stream PascalFrancis, to step Curation: 000895
to stream PascalFrancis, to step Checkpoint: 000302
to stream Main, to step Merge: 001D92
to stream Main, to step Curation: 001C77

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The α<sub>2</sub>
 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates</title>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Brain, Imaging, and Behaviour - Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Movement Disorders Clinic, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Piggott, Matthew J" sort="Piggott, Matthew J" uniqKey="Piggott M" first="Matthew J." last="Piggott">Matthew J. Piggott</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia</s1>
<s2>Crawley, Western Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Crawley, Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Savola, Juha Matti" sort="Savola, Juha Matti" uniqKey="Savola J" first="Juha-Matti" last="Savola">Juha-Matti Savola</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Santhera Pharmaceuticals (Switzerland) Ltd</s1>
<s2>Liestal</s2>
<s3>CHE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Santhera Pharmaceuticals (Switzerland) Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Brain, Imaging, and Behaviour - Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0474325</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0474325 INIST</idno>
<idno type="RBID">Pascal:10-0474325</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000382</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000895</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000302</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000302</idno>
<idno type="wicri:Area/Main/Merge">001D92</idno>
<idno type="wicri:Area/Main/Curation">001C77</idno>
<idno type="wicri:Area/Main/Exploration">001C77</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The α<sub>2</sub>
 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates</title>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Brain, Imaging, and Behaviour - Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Movement Disorders Clinic, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Piggott, Matthew J" sort="Piggott, Matthew J" uniqKey="Piggott M" first="Matthew J." last="Piggott">Matthew J. Piggott</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia</s1>
<s2>Crawley, Western Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Crawley, Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Savola, Juha Matti" sort="Savola, Juha Matti" uniqKey="Savola J" first="Juha-Matti" last="Savola">Juha-Matti Savola</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Santhera Pharmaceuticals (Switzerland) Ltd</s1>
<s2>Liestal</s2>
<s3>CHE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>Santhera Pharmaceuticals (Switzerland) Ltd</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Brain, Imaging, and Behaviour - Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Fipamezole</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Primates</term>
<term>α2-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Récepteur α2-adrénergique</term>
<term>Fipamézole</term>
<term>Lévodopa</term>
<term>Primates</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Reduction in the antiparkinsonian benefit of levodopa is a major complication of long-term levodopa treatment in advanced Parkinson's disease (PD). Such loss of benefit arises because of reduced duration of action and appearance of disabling dyskinesia. We assess the potential of the α<sub>2</sub>
 adrenergic antagonist fipamezole to reduce motor complications in parkinsonian macaques. MPTP-lesioned macaques were treated acutely with fipamezole (10 mg/kg) alone and in combination with two doses of levodopa. Fipamezole extended both duration and quality of antiparkinsonian action of levodopa. Duration of antiparkinsonian action, on time, was increased by up to 75% while "good-quality" on time, i.e., that not associated with disabling dyskinesia, was increased by up to 98%. Combination of fipamezole with the lower dose of levodopa provided antiparkinsonian benefit at least equivalent to that provided by the higher dose levodopa alone. However, with the combination, antiparkinsonian benefit was of much better quality. The proportion of on time without disabling dyskinesia (79%) was significantly greater than that with high dose levodopa alone (45%). Increased duration and quality of levodopa action may represent therapeutically valuable actions of α<sub>2</sub>
 adrenergic antagonists.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>Suisse</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
</noRegion>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</country>
<country name="Australie"><noRegion><name sortKey="Piggott, Matthew J" sort="Piggott, Matthew J" uniqKey="Piggott M" first="Matthew J." last="Piggott">Matthew J. Piggott</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Savola, Juha Matti" sort="Savola, Juha Matti" uniqKey="Savola J" first="Juha-Matti" last="Savola">Juha-Matti Savola</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C77 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C77 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:10-0474325
   |texte=   The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates

The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri